• Serum uric acid levels did not differ between the groups with and without urate deposits (498.67 vs 453.92 μmol/L). Symptom duration, however, was significantly longer in the urate deposits group (mean 107.63 vs 84.64 months). (renalandurologynews.com)
  • [ 140 ] In a retrospective study of 16,186 patients with initial serum uric acid levels above 7 mg/dL, Levy and colleagues found that patients with gout who remained on urate-lowering therapy were less likely to develop kidney damage leading to chronic kidney disease than those who were untreated. (medscape.com)
  • Hyperuricemia: Bempedoic acid may increase blood uric acid levels. (globenewswire.com)
  • Dotinurad suppresses uric acid reabsorption and lowers blood uric acid levels, by selectively inhibiting the urate transporter (URAT1) related to reabsorption of uric acid in the kidney. (eisai.com)
  • Dotinurad is a treatment for gout and hyperuricemia created by FUJI YAKUHIN CO., LTD. Dotinurad selectively inhibits URAT1 and has a small effect on other transporters, so it reduces serum uric acid levels at lower doses. (eisai.com)
  • It is indicated in combination with a xanthine oxidase inhibitor for hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. (medscape.com)
  • In adults, hyperuricemia occurs when the uric acid levels exceed 7 mg/dl. (yashodahospitals.com)
  • As uric acid levels increase, microscopic crystals of monosodium urate can appear out of the acid and lodge in the joints and surrounding tissue. (thegoutsite.com)
  • Gout is caused by the formation of urate crystals in body tissues. (healthline.com)
  • In addition, Hu et al reported that an elevated serum level of cancer antigen 72-4 (CA72-4)-a monoclonally-identified glycoprotein that has been noted to be elevated in adenocarcinomas and inflammatory diseases-is an independent risk factor for gout flares during initiation of urate-lowering therapy. (medscape.com)
  • It acts by inhibiting the urate transporter, URAT1, which is responsible for the majority of the renal reabsorption of uric acid. (medscape.com)
  • however, the presence of monosodium urate crystals in the joints determines a definitive diagnosis. (lifeextension.com)
  • 0.4 mmol/L]) that results in the precipitation of monosodium urate crystals in and around joints, most often causing recurrent. (msdmanuals.com)
  • Duzallo has received FDA approval as a once-daily oral treatment for hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically appropriate daily dose of allopurinol alone, Ironwood Pharmaceuticals, Inc. announced in a press release . (hcplive.com)
  • Duzallo is the first drug that combines the current standard of care for the treatment of hyperuricemia associated with gout-allopurinol-with the most recent FDA-approved treatment for this condition, lesinurad, the company stated. (hcplive.com)
  • Indicated for long-term management of hyperuricemia associated with gout. (medscape.com)
  • Used to treat and prevent hyperuricemia associated with gout and gouty arthritis. (medscape.com)
  • Although serum urate level did not differ between groups, modified Sharp/van der Heijde erosion scores were significantly higher in the group with vs without urate deposition. (renalandurologynews.com)
  • The aim of antihyperuricaemic treatment in chronic gout is to reduce plasma urate concentrations below the threshold of supersaturation of the extracellular tissue to stop the deposition of MSU crystals and allow the dissolution of existing ones. (bmj.com)
  • Gout (also called urate crystal deposition disease) is characterized by reduced renal clearance or, less frequently, an overproduction of uric acid. (unboundmedicine.com)
  • Nevertheless, hyperuricemia is the major risk factor for gout because it predisposes to urate crystal formation and deposition, particularly in and around joints and in other soft tissue structures. (unboundmedicine.com)
  • In addition, most patients with gout eventually require long-term treatment with urate-lowering therapy (ULT) to reverse the chronic urate crystal deposition and to prevent recurrent flares that can cause permanent joint damage. (unboundmedicine.com)
  • Intrarenal urate crystal deposition was absent in all groups. (ewha.ac.kr)
  • The American College of Rheumatology (ACR) published guidelines on the treatment and prophylaxis of acute gouty arthritis and the management of hyperuricemia. (medscape.com)
  • Several cohort and cross-sectional studies definitively established the relationship between hyperuricemia and the progress of DKD in either type 1 or type 2 diabetes [ 3 - 5 ]. (hindawi.com)
  • The independent risk relationship between hyperuricemia and acute MI is confirmed. (natap.org)
  • Among the 56 patients, 30 had urate deposits in the MTP joints of the feet and 26 did not, according to DECT. (renalandurologynews.com)
  • [ 140 ] The hazard ratio for kidney damage was 1.08 (95% confidence interval, 0.76-1.52) in patients who received urate-lowering therapy more than 80% of the time and was 1.27 (95% confidence interval, 1.05-1.55) in those who received urate-lowering therapy less than 80% of the time. (medscape.com)
  • In a study of gout flares in patients newly started on urate-lowering therapy, Rashid et al found that 68% of these patients had one or more gout flares during the first 12 months of therapy. (medscape.com)
  • Hyperuricemia may occur early in treatment and persist throughout treatment, and may lead to the development of gout, especially in patients with a history of gout. (globenewswire.com)
  • This was a pooled analysis of phase III trials on allopurinol and febuxostat, including 4101 patients with gout and hyperuricemia. (unboundmedicine.com)
  • In patients with gout and hyperuricemia, febuxostat was significantly more effective and faster than allopurinol in obtaining the recommended target sUA levels, which were reached by a higher number of patients. (unboundmedicine.com)
  • OBJECTIVES To study the efficacy of allopurinol and benzbromarone to reduce serum urate concentrations in patients with primary chronic gout. (bmj.com)
  • RESULTS Patients receiving allopurinol 300 mg/day showed a mean reduction of plasmatic urate of 2.75 mg/dl (from 8.60 to 5.85 mg/dl) and 3.34 mg/dl (from 9.10 to 5.76 mg/dl) in normal excretors and under excretors respectively. (bmj.com)
  • Patients receiving benzbromarone 100 mg/day achieved a reduction of plasmatic urate of 5.04 mg/dl (from 8.58 to 3.54 mg/dl). (bmj.com)
  • Fifty three per cent of patients receiving allopurinol and 100% receiving benzbromarone achieved optimal plasma urate concentrations at such doses. (bmj.com)
  • The patients with poor results with allopurinol 300 mg/day achieved a proper plasma urate concentration with allopurinol 450 to 600 mg/day, the mean final dose being 372 mg/day. (bmj.com)
  • Uricosuric treatment is a suitable approach to the treatment of patients with gout who show underexcretion of urate. (bmj.com)
  • The evidence of when to start urate lowering drug (ULD) treatment is conflicting: most authors support that ULD treatment should be considered after a first episode, 3 some advocate that only patients who suffer more than four episodes/year should be given ULDs, 8 and others that such a decision should be on an individual patient basis. (bmj.com)
  • By identifying patients who are at higher risk for hyperuricemia , pharmacists can monitor patients when suspected agents are added to their regimen. (goutpal.com)
  • Garrod showed elevated SU concentration in gout patients in 1848 [14], and hyperuricemia has since been established as the cause of gout. (researchgate.net)
  • About 20% of patients with gout have urinary tract stones and can develop an interstitial urate nephropathy. (unboundmedicine.com)
  • Getting patients with gout to serum urate goal, and keeping them at or below goal, are essential to success in treating these patients. (hcplive.com)
  • Furthermore, it is estimated that currently in China, the number of patients with hyperuricemia is approximately 190 million and the number of patients with gout is approximately 16 million. (eisai.com)
  • Following commercialization, Eisai will aim to contribute to patients with hyperuricemia that is unmet medical needs by utilizing the knowledge and networks that Eisai has cultivated through its China business. (eisai.com)
  • Through the development and commercialization of dotinurad, Eisai and FUJI YAKUHIN will provide new treatment options for hyperuricemia and gout in China and contribute to improving the quality of life of patients. (eisai.com)
  • Identifying factors associated with hyperuricemia in CKD patients would help determine interventions to reduce CKD mortality, particularly in resources limited countries. (biomedcentral.com)
  • We sought to determine the prevalence and factors associated with hyperuricemia in non-dialysed CKD adult patients in Cameroon. (biomedcentral.com)
  • In this sample of non-dialysed CKD patients in Cameroon, about 7 out of 10 had hyperuricemia. (biomedcentral.com)
  • In CKD patients, factors associated with hyperuricemia have not been fully elucidated. (biomedcentral.com)
  • We therefore sought to determine the prevalence and factors associated with hyperuricemia in non-dialysed adult CKD patients in Cameroon, in order to generate findings that would help determine interventions to reduce CKD mortality, particularly in resources limited countries. (biomedcentral.com)
  • Pharmacotherapy for hyperuricemia is based on whether patients are overproducers or undersecretors. (medscape.com)
  • Since losartan has been found to have an uricosuric property, it may be worthwhile to use it in hypertensive patients with hyperuricemia that lack any contraindication to angiotensin receptor blockers. (medscape.com)
  • Methods: In the arterial stiffness, urate and urinary proteomic studies, patients with severe obesity, were assessed at baseline and at follow-up. (bl.uk)
  • In the urate study, serum urate was associated with OSA in severely obese females and there was a trend for reduced urate levels in CPAP-treated patients. (bl.uk)
  • Differences in production of serum urate or a more rapid decline in fractional excretion of serum urate are potential, albeit still unproven, explanations for these findings in African-American women. (umn.edu)
  • Competition between urate and lactate for renal tubule excretion accounts for the lactic acidemia. (medscape.com)
  • 1] Hyperuricemia is caused either by accelated generation of uric acid through purine metabolism or by impaired excretion in the kidney, or by high levels of fructose in the diet. (goldbamboo.com)
  • URAT1, a molecular therapeutic target for gout/hyperuricemia, was initially derived from research into hereditary renal hypouricemia (RHUC). (researchgate.net)
  • The observation that longstanding hyperuricemia is associated with chronic tubulointerstitial disease and intrarenal vaso-constriction raised the hypothesis that hyperuricemia might contribute to chronic CSA nephropathy. (ewha.ac.kr)
  • The effect of hyperuricemia on CSA nephropathy was determined by blocking the hepatic enzyme uricase with oxonic acid (CSA-OA). (ewha.ac.kr)
  • If urate levels remain high, flares can recur, affecting additional joints throughout the body. (medlineplus.gov)
  • After sustained hyperuricemia, these MSU crystals deposit in tendons and joints to cause severe diseases including gout, kidney stones and several forms of kidney disease. (salimetrics.com)
  • These discoveries have prompted research interest in SU and xanthine oxidoreductase (XOR), an enzyme that produces both urate and ROSs, as status or progression biomarkers of chronic kidney disease and cardiovascular disease. (researchgate.net)
  • Over time, untreated or insufficiently treated gout may progress, with more frequent flares and formation of urate crystal deposits (tophi) and associated chronic, deforming arthritis (gouty arthropathy). (unboundmedicine.com)
  • The symptoms and signs of gout result from acute and chronic inflammatory responses of the body to urate crystal deposits. (unboundmedicine.com)
  • Gout is a chronic disease that is caused due to excess accumulation of uric acid in the body, a condition referred to as hyperuricemia. (abnewswire.com)
  • People with gout have high levels of a substance called urate in the blood (hyperuricemia). (medlineplus.gov)
  • Many gout-associated genes play a role in releasing urate into the urine if levels are too high or reabsorbing it back into the bloodstream if more is needed in the body. (medlineplus.gov)
  • Of all the genes that have been studied, two genes, SLC2A9 and ABCG2 , seem to have the greatest influence on urate levels. (medlineplus.gov)
  • The SLC2A9 gene provides instructions for making a protein that is found primarily in the kidneys where it plays a role in managing the body's levels of urate. (medlineplus.gov)
  • Blood uric levels above 7 mg/dl leads to the formation of monosodium urate (MSU) crystals. (salimetrics.com)
  • Gout results from elevated serum urate (SU) levels, or hyperuricemia, and is a globally widespread and increasingly burdensome disease. (researchgate.net)
  • Likewise, in severely obese individuals with OSA who have hyperuricaemia or recurrent gout, there may be a need to consider OSA assessment as elevated urate levels are associated with increased cardiovascular risk. (bl.uk)
  • Hyperuricemia is the presence of high levels of uric acid in the blood. (goldbamboo.com)
  • The root cause of gout is high levels of uric acid circulating in the bloodstream, a condition called hyperuricemia . (thegoutsite.com)
  • Normally, male UA levels greater than 7 mg/dL or female UA levels greater than 6 mg/dL are considered to be hyperuricemia (Hao et al. (cmeindia.in)
  • This accounts for the hyperuricemia observed during an acute episode. (medscape.com)
  • To determine if hyperuricemia and gouty arthritis are independent risk factors for acute myocardial infarction (MI) and, if so, whether they are independent of renal function, diuretic use, metabolic syndrome, and other established risk factors. (natap.org)
  • Hyperuricemia was an independent risk factor for acute MI in the multivariable regression models, with an odds ratio (OR) of 1.11 (95% confidence interval [95% CI] 1.08-1.15, P (natap.org)
  • In separate analyses, a relationship between gout and the risk of acute MI was evident among those with and without those hyperuricemia. (natap.org)
  • The risk of gout flares emphasizes the importance of providing close coverage, patient education, and prophylaxis, especially during the first year of urate-lowering therapy. (medscape.com)
  • Genetic changes in the SLC2A9 gene that can result in hyperuricemia increase the reabsorption of urate into the bloodstream and decrease its release into the urine. (medlineplus.gov)
  • As the condition worsens, urate crystals can also be deposited under the skin or in other soft tissue, forming a nodule called a tophus (plural: tophi). (medlineplus.gov)
  • The clinical manifestations of gout are linked to the formation of monosodium urate (MSU) crystals, which are both responsible for the inflammatory manifestations as well as the joint damage produced by tophi. (bmj.com)
  • Confounding factors examined included: age at enrollment, body mass index, development of hypertension, glomerular filtration rate, medication use, diet and alcohol intake and menopausal symptoms in women.Results: Referent to whites, African-American men and women had significantly lower concentrations of serum urate at baseline. (umn.edu)
  • African-American women developed a significantly increased risk of hyperuricemia when compared to white women (HR = 2.31 (1.34 to 3.99)).Conclusions: Young African-American men and women had lower concentrations of serum urate than whites. (umn.edu)
  • During longitudinal follow-up, African-American women had a significantly increased risk of developing hyperuricemia when compared with white women, a difference that was not observed in men. (umn.edu)
  • Bone erosion occurred in both groups but was significantly more severe in the group with than without urate deposits, with a mean overall erosion score of 14.27 vs 1.38, Gui-Hua Jiang, MD, of The Affiliated Guangdong Second Provincial General Hospital of Jinan University in Guangzhou, China, and colleagues reported in Frontiers in Endocrinology . (renalandurologynews.com)
  • Introduction: Findings that African-American race/ethnicity is associated with higher concentrations of serum urate have not been adjusted for possible confounding factors or have not explored this question as a primary outcome. (umn.edu)
  • After achieving steady plasma urate concentrations with such doses, treatment was then adjusted to obtain optimal plasmatic urate concentrations (under 6 mg/dl). (bmj.com)
  • CONCLUSION Benzbromarone is very effective to control plasma urate concentrations at doses ranging from 50 to 100 mg/day. (bmj.com)
  • This study was carried out to compare the efficacy of allopurinol and benzbromarone, in lowering plasma urate concentrations below those considered therapeutic for the dissolution of MSU crystals in tissues, 12-16 using a pathogenic approach. (bmj.com)
  • Monosodium urate (MSU) crystal deposits correlate with the degree of bone erosion displayed on dual-energy computed tomography (DECT), which may identify gout progression and joint damage earlier. (renalandurologynews.com)
  • In addition, hyperuricemia is known to be associated with various diseases in the urinary system, endocrine system, metabolic system, cardio-cerebrovascular system etc., including gout. (eisai.com)
  • We tested this hypothesis in a bi-racial cohort of younger African-American and white men and women.Methods: Data from 5,049 participants at the Coronary Artery Risk Development in Young Adults (CARDIA) cohort baseline (1985 to1986) and follow-up for up to 20 years of individuals without hyperuricemia (defined as a serum urate of 6.8 mg/dL or more) at baseline were utilized. (umn.edu)
  • These data confirm that rasburicase is effective and safe for the treatment and prophylaxis of children and adults with malignancy-associated hyperuricemia. (wustl.edu)
  • trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia. (wikipedia.org)
  • Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. (globenewswire.com)
  • Therefore, febuxostat was confirmed as an effective option for the treatment of hyperuricemia in gout. (unboundmedicine.com)
  • Recent studies have illuminated the pathophysiology of gout/hyperuricemia and its epidemiology, diagnosis, treatment, and complications. (researchgate.net)
  • Urece is indicated for the treatment of gout and hyperuricemia. (pharmaceutical-technology.com)
  • This represents an important and needed new option in the treatment of hyperuricemia. (hcplive.com)
  • Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and FUJI YAKUHIN CO., LTD. (Headquarters: Saitama, CEO: Masayuki Takayanagi, "FUJI YAKUHIN") announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in China. (eisai.com)
  • Urate-lowering therapy appears to reduce the incidence of kidney damage in gout. (medscape.com)
  • Hyperuricemia frequently complicates cyclosporine (CSA) therapy. (ewha.ac.kr)
  • Hyperuricemia is also very common among adult men and postmenopausal women, most of whom remain asymptomatic with respect to gout throughout their lives. (unboundmedicine.com)
  • CSA treated rats developed mild hyperuricemia with arteriolar hyalinosis, tubular injury and striped interstitial fibrosis. (ewha.ac.kr)
  • The caricature of the typical patient with hyperuricemia is an obese middle-aged man with hypertension, diabetes mellitus, and hyperlipidemia who is given to excessive drinking. (natap.org)
  • In some studies hyperuricemia is present in 40 to 60% of subjects with untreated hypertension. (cmeindia.in)
  • Conclusion: Hyperuricemia is associated with an increased risk for incident hypertension, independent of traditional hypertension risk factors. (cmeindia.in)
  • Hyperuricemia increased the relative risk of hypertension by approximately 30% in men under 60 and by 2.6-fold in women under 40. (cmeindia.in)
  • As the authors mention, this strongly suggests that there may be a specific link between cardiopulmonary physiology and hyperuricemia , and this finding fits nicely with studies that have already found associations between pulmonary hypertension and hyperuricemia. (medscape.com)
  • Suitable animal models characterized by both diabetes and hyperuricemia should be explored for researches in this field. (hindawi.com)
  • Hyperuricemia is the second most common metabolic disease after diabetes mellitus in China. (eisai.com)
  • Objetivo: investigar los efectos de una sal baja en sodio combinada con la versión china de la dieta DASH (del inglés Dietary Approaches to StopHypertension) modificada en la función cerebrovascular en pacientes con hipertensión y diabetes tipo 2. (bvsalud.org)